Gediminas Gliebus, MD
Neurology · Boca Raton, FLNPI 1174789044
Payments from drug & device makers
What this record shows
This record is dominated by other: $99,900 of the $120,795 with a category attached, or 82.7%. Brainscope Company, Inc. accounts for 82.7% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2021 at $107,268 and has fallen 99.7% since, to $288 in 2025. Among neurology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 47 payments — averaging $2570.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Brainscope Company, Inc.$100K
- Biogen$10K
- Eisai Inc.$9K
- Canon Medical Systems USA, Inc.$1K
- Cerapedics Inc.$113
- Lundbeck LLC$95
- plus $308 from 8 others
Across 14 payments — averaging $12,685 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$97K
- Genentech, Inc.$80K
What the payments were for
- Consulting fees$1,1301%
- Speaking & faculty fees$16,82014%
- Travel & lodging$1,9872%
- Food & beverage$9361%
- Education$220%
- Other$99,90083%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Brainscope Company, Inc. | 1 | $99,900 |
| Biogen | 7 | $10,170 |
| Eisai Inc. | 13 | $8,874 |
| Canon Medical Systems USA, Inc. | 2 | $1,336 |
| Cerapedics Inc. | 1 | $113 |
| Lundbeck LLC | 4 | $95 |
| Acadia Pharmaceuticals Inc | 6 | $94 |
| Supernus Pharmaceuticals, Inc. | 4 | $51 |
| Amneal Pharmaceuticals LLC | 3 | $43 |
| Novartis | 2 | $29 |
| Lilly USA, LLC | 1 | $26 |
| Sunovion Pharmaceuticals Inc. | 1 | $23 |
| TG Therapeutics, Inc. | 1 | $22 |
| AbbVie | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BrainScope One$99,900
- Leqembi$8,554
- I-FACTOR PEPTIDE ENHANCED BONE GRAFT$113
How this compares
$120,795 in reported general payments places this provider in the 95th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 11 | $56,382 |
| Memantine Hcl ErMemantine Hcl | 199 | $14,506 |
| Emgality PenGalcanezumab-Gnlm | 13 | $13,283 |
| Rivastigmine | 38 | $8,297 |
| Donepezil Hcl | 622 | $7,370 |
| Memantine Hcl | 152 | $4,206 |
| Levetiracetam | 65 | $3,968 |
| RivastigmineRivastigmine Tartrate | 66 | $3,397 |
| Carbamazepine ErCarbamazepine | 23 | $2,854 |
| Oxcarbazepine | 23 | $1,502 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 94 | $1,383 |
| Mirtazapine | 57 | $1,128 |
| Carbamazepine | 15 | $1,031 |
| Gabapentin | 60 | $991 |
| Escitalopram Oxalate | 77 | $806 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $94 | $56,38211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,434 neurology providers in Florida.
Other neurology in Boca Raton
- Stuart IsaacsonBoca Raton$3.9M
- Brian SteingoBoca Raton$792K
- Richard IsaacsonBoca Raton$127K
- Selim BenbadisTampa$2.1M
- Derrick RobertsonTampa$1.8M
- Robert HauserTampa$1.6M
- David RoseTampa$1.4M
- Matthew BakerNaples$1.4M
- Donald NegroskiSarasota$1.4M
- Mark CascioneTampa$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.